Immunocore Holdings Stock Analysis

IMCR Stock  USD 58.47  1.16  2.02%   
Immunocore Holdings is undervalued with Real Value of 68.02 and Target Price of 81.67. The main objective of Immunocore Holdings stock analysis is to determine its intrinsic value, which is an estimate of what Immunocore Holdings is worth, separate from its market price. There are two main types of Immunocore Holdings' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Immunocore Holdings' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Immunocore Holdings' stock to identify patterns and trends that may indicate its future price movements.
The Immunocore Holdings stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immunocore Holdings is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Immunocore Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Immunocore Holdings' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Stock Analysis Notes

About 84.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.4. Immunocore Holdings had not issued any dividends in recent years. Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Immunocore Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people. To learn more about Immunocore Holdings call Bahija Jallal at 44 12 3543 8600 or check out https://www.immunocore.com.

Immunocore Holdings Quarterly Total Revenue

105.64 Million

Immunocore Holdings Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunocore Holdings' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunocore Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunocore Holdings generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 249.43 M. Net Loss for the year was (55.29 M) with profit before overhead, payroll, taxes, and interest of 54.11 M.
Over 84.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Immunocore Holdings plc Stock Holdings Lessened by Allspring Global Investments Holdings LLC - MarketBeat

Immunocore Holdings Upcoming and Recent Events

Earnings reports are used by Immunocore Holdings to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunocore Holdings previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Immunocore Largest EPS Surprises

Earnings surprises can significantly impact Immunocore Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-12
2021-03-31-0.83-0.92-0.0910 
2021-03-25
2020-12-31-1.05-0.820.2321 
2022-03-03
2021-12-31-82.21-91.0-8.7910 
View All Earnings Estimates

Immunocore Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunocore Holdings is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunocore Holdings backward and forwards among themselves. Immunocore Holdings' institutional investor refers to the entity that pools money to purchase Immunocore Holdings' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Fiera Capital Corporation2023-12-31
846.8 K
Pictet Asset Manangement Sa2023-12-31
809.6 K
Blackrock Inc2023-12-31
779 K
Bill & Melinda Gates Foundation2023-12-31
576.9 K
Cowen And Company, Llc2023-12-31
536.5 K
Polar Capital Holdings Plc2023-12-31
501.3 K
Principal Financial Group Inc2023-12-31
483.3 K
Tang Capital Management Llc2023-09-30
405.6 K
Logos Global Management Lp2023-12-31
400 K
Rtw Investments, Llc2023-12-31
6.1 M
Wellington Management Company Llp2023-12-31
4.3 M
Note, although Immunocore Holdings' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunocore Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunocore Holdings's market, we take the total number of its shares issued and multiply it by Immunocore Holdings's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Immunocore Profitablity

Immunocore Holdings' profitability indicators refer to fundamental financial ratios that showcase Immunocore Holdings' ability to generate income relative to its revenue or operating costs. If, let's say, Immunocore Holdings is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunocore Holdings' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunocore Holdings' profitability requires more research than a typical breakdown of Immunocore Holdings' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.22) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.26.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.09)(0.1)
Return On Capital Employed(0.13)(0.14)
Return On Assets(0.09)(0.1)
Return On Equity(0.15)(0.16)

Management Efficiency

Immunocore Holdings has return on total asset (ROA) of (0.0674) % which means that it has lost $0.0674 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1562) %, meaning that it created substantial loss on money invested by shareholders. Immunocore Holdings' management efficiency ratios could be used to measure how well Immunocore Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/25/2024, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Immunocore Holdings' Net Tangible Assets are relatively stable compared to the past year. As of 04/25/2024, Other Current Assets is likely to grow to about 12.3 M, while Total Current Assets are likely to drop slightly above 270.4 M.
Last ReportedProjected for Next Year
Book Value Per Share 0.01  0.01 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 0.01  0.01 
Enterprise Value Over EBITDA-86.8 K-82.5 K
Price Book Value Ratio9.1 K15.7 K
Enterprise Value Multiple-86.8 K-82.5 K
Price Fair Value9.1 K15.7 K
Enterprise Value3.3 T3.5 T
The analysis of Immunocore Holdings' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Immunocore Holdings' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Immunocore Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.889

Technical Drivers

As of the 25th of April, Immunocore Holdings retains the Risk Adjusted Performance of (0.07), standard deviation of 2.3, and Market Risk Adjusted Performance of (0.29). Immunocore Holdings technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down thirteen technical drivers for Immunocore Holdings, which can be compared to its competitors. Please check out Immunocore Holdings variance and potential upside to decide if Immunocore Holdings is priced fairly, providing market reflects its last-minute price of 58.47 per share. Given that Immunocore Holdings has information ratio of (0.16), we strongly advise you to confirm Immunocore Holdings's regular market performance to make sure the company can sustain itself at a future point.

Immunocore Holdings Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immunocore Holdings middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immunocore Holdings. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Immunocore Holdings Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunocore Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunocore Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunocore Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunocore Holdings Predictive Daily Indicators

Immunocore Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunocore Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Immunocore Holdings Corporate Filings

12th of April 2024
Other Reports
ViewVerify
5th of April 2024
Other Reports
ViewVerify
F4
3rd of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
2nd of April 2024
Other Reports
ViewVerify
ASR
21st of March 2024
Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC)
ViewVerify
13A
11th of March 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
F3
7th of March 2024
An amendment to the original Schedule 13D filing
ViewVerify
F4
1st of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Immunocore Holdings Forecast Models

Immunocore Holdings' time-series forecasting models are one of many Immunocore Holdings' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunocore Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Immunocore Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunocore Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunocore shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunocore Holdings. By using and applying Immunocore Stock analysis, traders can create a robust methodology for identifying Immunocore entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.24)(0.26)
Operating Profit Margin(0.24)(0.25)
Net Loss(0.22)(0.23)
Gross Profit Margin 1.00  1.05 

Current Immunocore Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunocore analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunocore analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
81.67Strong Buy17Odds
Immunocore Holdings current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunocore analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunocore stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunocore Holdings, talking to its executives and customers, or listening to Immunocore conference calls.
Immunocore Analyst Advice Details

Immunocore Stock Analysis Indicators

Immunocore Holdings stock analysis indicators help investors evaluate how Immunocore Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunocore Holdings shares will generate the highest return on investment. By understating and applying Immunocore Holdings stock analysis, traders can identify Immunocore Holdings position entry and exit signals to maximize returns.
Begin Period Cash Flow402.5 M
Long Term Debt48 M
Common Stock Shares Outstanding48.9 M
Total Stockholder Equity368.8 M
Tax Provision2.4 M
Quarterly Earnings Growth Y O Y-0.677
Property Plant And Equipment Net42.7 M
Cash And Short Term Investments442.6 M
Cash442.6 M
Accounts Payable17.8 M
Net Debt-358.6 M
50 Day M A63.3124
Total Current Liabilities139 M
Other Operating Expenses309.1 M
Non Current Assets Total68.2 M
Non Currrent Assets Other14.5 M
Stock Based Compensation32.5 M
When determining whether Immunocore Holdings is a strong investment it is important to analyze Immunocore Holdings' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunocore Holdings' future performance. For an informed investment choice regarding Immunocore Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.
Note that the Immunocore Holdings information on this page should be used as a complementary analysis to other Immunocore Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Immunocore Stock analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Is Immunocore Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunocore Holdings. If investors know Immunocore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunocore Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.68)
Earnings Share
(1.40)
Revenue Per Share
5.102
Quarterly Revenue Growth
0.122
Return On Assets
(0.07)
The market value of Immunocore Holdings is measured differently than its book value, which is the value of Immunocore that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocore Holdings' value that differs from its market value or its book value, called intrinsic value, which is Immunocore Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocore Holdings' market value can be influenced by many factors that don't directly affect Immunocore Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocore Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunocore Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocore Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.